Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease

January 6, 2020 updated by: ADIR Association

Chronic obstructive pulmonary disease is a leading cause of mortality worldwide.

It is a systemic disease which includes pulmonary, cardiac, muscular, digestive and cognitive impairments.

Pulmonary rehabilitation is a symptomatic treatment to reduce dyspnea and functional incapacity. However, it effects on cognitive dysfunction are not well known.

The aim of this study is to assess the effects of a comprehensive pulmonary rehabilitation program on cognitive dysfunction in patients with severe to very severe chronic obstructive pulmonary disease using the Montreal Cognitive Assessment tool.

Study Overview

Status

Completed

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

56

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bois-Guillaume, France, 76230
        • Bonnevie
      • Le Havre, France, 76600
        • Médrinal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Every patients with chronic obstructive pulmonary disease referred for pulmonary rehabilitation in ADIR Association (Rouen, France) and the Groupe Hospitalier du Havre (Le Havre, France) will be assessed for eligibility.

Description

Inclusion Criteria:

  • Age > 18years;
  • Chronic obstructive pulmonary disease stade III to IV;
  • Referred for pulmonary rehabilitation.

Non Inclusion Criteria:

  • Pregnancy or likely to be;
  • History of psychiatric, neuro-vascular, cognitive disease or cranial trauma;
  • Active alcoholism;
  • Guardianship;
  • Hospitalisation for acute exacerbation of chronic obstructive pulmonary disease in the previous 4 weeks;

Exclusion Criteria:

  • Interruption of the pulmonary rehabilitation program > 15 days;
  • Disruption of the training before the 18th session;
  • Less than 18 sessions in four month.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Pulmonary rehabilitation
The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
See group description.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Baseline cognitive function
Time Frame: Cognitive function is assessed at the beginning of the rehabilitation program : day 0
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function is assessed at the beginning of the rehabilitation program : day 0
Cognitive function after pulmonary rehabilitation
Time Frame: Cognitive function is assessed at the end of the rehabilitation program : day 60
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function is assessed at the end of the rehabilitation program : day 60
Cognitive function : follow up
Time Frame: Cognitive function is assessed 3 month after rehabilitation : day 150
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Cognitive function is assessed 3 month after rehabilitation : day 150
Change in cognitive function from baseline to the end of pulmonary rehabilitation
Time Frame: Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Change in cognitive function from baseline to the end of pulmonary rehabilitation is assessed with end of pulmonary rehabilitation minus baseline values (day 60 - day 0)
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up
Time Frame: Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)
Cognitive function is assessed with the Montreal Cognitive Assessement tool
Change in cognitive function from the end of pulmonary rehabilitation to 3 month of follow up is assessed with the 3 month of follow minus the end of pulmonary rehabilitation values (day 150 - day 60)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anxiety and depression : baseline
Time Frame: Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression are assessed at the beginning of the rehabilitation program : day 0
Anxiety and depression : end of pulmonary rehabilitation
Time Frame: Anxiety and depression are assessed at the end of the rehabilitation program : day 60
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression are assessed at the end of the rehabilitation program : day 60
Anxiety and depression : follow up
Time Frame: Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
Anxiety and depression are assessed with the Hospital Anxiety and Depression scale (HAD).
Anxiety and depression are assesses 3 month after the end of pulmonary rehabilitation program : day 150
Quality of life : baseline
Time Frame: Quality of life is assessed at the beginning of the rehabilitation program : day 0
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life is assessed at the beginning of the rehabilitation program : day 0
Quality of life : end of pulmonary rehabilitation
Time Frame: Quality of life is assessed at the end of the rehabilitation program : day 60
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life is assessed at the end of the rehabilitation program : day 60
Quality of life : follow-up
Time Frame: Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
Quality of life is assessed using the Saint Georges Respiratory Questionnaire
Quality of life is assessed 3 month after the end of the rehabilitation program : day 150
Functional capacity (six-minute stepper test) : baseline
Time Frame: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Functional capacity is assessed with the six-minute stepper test
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Functional capacity (six-minute stepper test) : end of pulmonary rehabilitation
Time Frame: Functional capacity is assessed at the end of the rehabilitation program : day 60
Functional capacity is assessed with the six-minute stepper test
Functional capacity is assessed at the end of the rehabilitation program : day 60
Functional capacity (six-minute walk test) : baseline
Time Frame: Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Functional capacity is assessed with the six-minute walk test
Functional capacity is assessed at the beginning of the rehabilitation program : day 0
Adherence
Time Frame: Adherence is assessed at the end of the rehabilitation program : day 60
Adherence to the pulmonary rehabilitation program is assessed by the following equation : number of session performed divided by the number of scheduled sessions
Adherence is assessed at the end of the rehabilitation program : day 60
Relation between the cognitive function and the respiratory function (forced expiratory volume in 1 second)
Time Frame: The relation is assessed between baseline demographic data at day 0
Cognitive function is assessed with the Montreal Cognitive Assessement tool and respiratory function is assessed with spirometric evaluation
The relation is assessed between baseline demographic data at day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cuvelier Antoine, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.
  • Study Chair: Muir Jean-François, Prof, PhD, CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; ADIR Association, Bois-Guillaume, France.
  • Study Chair: Tardif Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France
  • Study Chair: Viacroze Catherine, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
  • Study Chair: Debeaumont David, MD, CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de physiologie urinaire, digestive, respiratoire et sportive, Bois-Guillaume, France.
  • Study Chair: Patout Maxime, MD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France
  • Study Chair: Lamia Bouchra, Prof, PhD, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France ; Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France.
  • Study Chair: Quieffin Jean, MD, Service de pneumologie, Hôpital Jacques Monod 76290 Montivilliers.
  • Study Chair: Prieur Guillaume, PT, MsC, Service de pneumologie, Groupe Hospitalier du Havre, Fr
  • Study Chair: Médrinal Clément, PT, MsC, UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France. Service de réanimation, Groupe Hospitalier du Havre, France
  • Study Chair: Gravier Francis-Edouard, PT, ADIR Association, Bois-Guillaume, France
  • Study Chair: Bonnevie Tristan, PT, MsC, ADIR Association, Bois-Guillaume, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 4, 2017

Primary Completion (Actual)

December 1, 2019

Study Completion (Actual)

December 1, 2019

Study Registration Dates

First Submitted

July 31, 2017

First Submitted That Met QC Criteria

August 8, 2017

First Posted (Actual)

August 9, 2017

Study Record Updates

Last Update Posted (Actual)

January 7, 2020

Last Update Submitted That Met QC Criteria

January 6, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

Clinical Trials on Pulmonary rehabilitation

3
Subscribe